Cover Image

慢性淋巴性白血病:KOL (關鍵意見領袖) 分析

Chronic Lymphocytic Leukaemia: KOL Insight

出版商 FirstWord 商品編碼 304343
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
慢性淋巴性白血病:KOL (關鍵意見領袖) 分析 Chronic Lymphocytic Leukaemia: KOL Insight
出版日期: 2016年08月01日 內容資訊: 英文

本報告以慢性淋巴性白血病 (CLL)的6種已上市藥物及開發後期的7種藥物為研究主題,提供北美及歐洲的12名關鍵意見領袖(KOL) 的各種見解彙整。


  • Venclexta (venetoclax:AbbVie/Roche)
  • Imbruvica (ibrutinib:AbbVie/Johnson & Johnson)
  • Acalabrutinib (Acerta Pharmaceuticals/AstraZeneca)
  • TGR-1202 (TG Therapeutics)等


  • 抗CD20單株抗體藥、化療藥:作為一線治療目前的主流
    • 變成化療藥的一線治療的選項
    • 被認為是有前途的藥物與其理由
  • Imbruvica:得到有效性高的評價,不過,治療計劃的不定性是缺點
    • KOL摸索作為未來的治療藥的東西
    • 新的臨床研究如何影響該考察的可能性
  • KOL:要求聯合治療更進一步的研究
    • 關於並用藥對現有的治療範例的影響,專家的想法
  • CLL治療藥的毒性相關的專家疑慮
  • KOL對CLL治療藥的Rituximab生技仿製藥的利用的見解
  • 專家贊同到目前為止Acalabrutinib的有效性極佳
  • CLL的「改變遊戲規則者」的Venclexta
    • Venclexta的評價非常高之中KOL對其他的開發平台藥物的看法?
  • Revlimid及CDK抑制劑提供新的作用機制和專家指摘等


Product Code: 596200636

How will established and emerging agents reshape the CLL treatment landscape?

How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will Gazyva's/Gazyvaro's superior efficacy compared to Rituxan/MabThera influence prescribing decisions? How will familiarity, convenience and tolerability influence Imbruvica's continued uptake? What pipeline therapies do KOLs have their eyes on? Do KOLs predict a significant change in the CLL treatment paradigm in the future?

Covering 6 marketed drugs and 7 late-stage pipeline therapies, this report reveals candid insights about the CLL landscape from 12 KOLs in North America and Europe. You'll learn which treatments KOLs consistently choose (and why!), what influences their prescribing of other treatment options, and which pipeline drugs they're most excited about.

“Everything will change. How we will be treating our patients in one year to 18 months will be completely different. Venclexta is coming. Maybe we will be treating all patients in first-line with the BTK inhibitors, and we will be treating all patients in the relapsed/refractory setting with Venclexta.” US KOL.

Take a tour of the report now:

  • The table of contents
  • The key questions answered
  • The key KOL quotes
  • See the 13 therapies covered
  • Find out who the 12 EU & US KOLs are
  • Review an extract from the report - 1 drug profile

Sample of brands covered:

  • Venclexta (venetoclax, AbbVie/Roche)
  • Imbruvica (ibrutinib, AbbVie/Johnson & Johnson)
  • Acalabrutinib (Acerta Pharmaceuticals/AstraZeneca)
  • TGR-1202 (TG Therapeutics)
  • Plus 9 more

Sample of KOLS interviewed

  • Michael J. Keating. Professor of Medicine and Internist, University of Texas MD Anderson Cancer Center, TX.
  • Daniel Catovsky. Emeritus Professor and Fellow, Institute of Cancer Research, London, UK.
  • Emili Montserrat. Professor of Medicine and Director of the Institute of Haematology and Oncology, Hospital Clinic of Barcelona, Spain.
  • Anthony R. Mato. Assistant Professor of Medicine, Hospital of the University of Pennsylvania, PA.
  • Plus 8 more - download the full list now

Top Takeaways

  • Anti-CD20 mAb therapy and chemotherapy dominate at first line - for now. KOLs want to see chemotherapies in first-line replaced by other options. Which agents do they find particularly exciting, and why?
  • While Imbruvica gets high marks for efficacy, its indeterminate treatment schedule is a drawback. What else are KOLs looking for in future treatments? And how could new clinical studies influence thinking?
  • KOLs would like to see more investigation into combination therapy regimens. Find out how experts think combinations could challenge established treatment paradigms.
  • Experts are concerned about the toxicity of CLL treatments. Have FDA safety alerts relegated Zydelig to last-resort status? Will unanswered questions affect the uptake of emerging treatment choices?
  • KOLs provide their views on the use of rituximab biosimilars as treatments for CLL. Should a rituximab biosimilar be approved as a treatment for CLL via indication extrapolation, will it be used? Will cost be the key driver of uptake? Or will Gazyva's/Gazyvaro's superior efficacy limit adoption of rituximab biosimilars altogether?
  • Experts concur that the efficacy reported with acalabrutinib to date is impressive. But do they think it could completely replace Imbruvica in CLL? If not, why not?
  • Venclexta is a ‘game-changer' in CLL. In the context of high enthusiasm for Venclexta, how do KOLs perceive other pipeline agents, in particular PI3K delta or dual inhibitors of P13K delta/gamma?
  • Experts note that Revlimid and CDK inhibitors offer novel mechanisms of action. Are they impressed, and will these options have any potential in CLL?
Back to Top